TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

17 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

17 studies on the map

Molecular Signatures of Cutaneous Dupilumab Response — University of California, San Francisco, San FranciscoSafety and Efficacy of Combination Belimumab and Voclosporin in the Treatment of Proliferative Forms of Lupus Glomerulopathy: Synergy Trial — AARA Clinical Research, GlendaleDapagliflozin in Active Lupus Nephritis — Massachusetts General Hospital, BostonDupilumab De-escalation in Pediatric Atopic Dermatitis — Johns Hopkins Univerisity, BaltimoreTrial of Belimumab in Early Lupus — Feinstein Institute, ManhassetPRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis — Purushotham & Akther Kotha MD, Inc., La MesaFibrosis Lessens After Metabolic Surgery — Banner Health Center, PhoenixA Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE) — GSK Investigational Site, AnnistonLebrikizumab in Moderate-to-severe Atopic Dermatitis — Physioseq USA - CA, FolsomEthnic Differences in Mechanisms of Action of Dupilumab — University of Michigan, Ann ArborSafety of the Herpes Zoster Subunit Vaccine in Lupus — NYU Langone Health, New YorkSafety and Efficacy of ONT01 in Lupus — Hospital for Special Surgery, New YorkProspective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users — Research Site, Las VegasUsing Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis — Lurie Children's Hospital/Northwestern University, ChicagoDupixent and Narrowband UVB for Atopic Dermatitis — Eczema Treatment Center of New Jersey, East WindsorQuantifying Hepatic Mitochondrial Fluxes in Humans — Texas Diabetes Institute - University Health System, San AntonioA Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132 — Local Institution - 0001, Farmington